


Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular)



Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular)



ISBN: 978-1-945584-30-5

28 October 2021

Submitted to the PQRI Development Technical Committee, PQRI Steering Committee and US Food and Drug Administration by the PQRI PODP Leachables and Extractables Working Group



Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular)

28 October 2021

**Submitted to the PQRI Development Technical Committee,
PQRI Steering Committee and US Food and Drug Administration
by the
PQRI PODP Leachables and Extractables Working Group**

Forward

Leachables in drug products that originate from the components used in packaging, delivery and manufacturing systems can compromise the quality of drug products and impact patient safety. The materials of construction associated with these components should be assessed for suitability in early drug development phases based on extractable profiles and correlated to potential and confirmed leachables. In 1999 the PQRI Leachables and Extractables (L&E) Working Group was established with the goal of reducing leachable uncertainty in Orally Inhaled and Nasal Drug Products (OINDP), using a science and risk based approach. The Working Group was made up of highly experienced scientists including toxicologists, analytical chemists, and others, from industry, government, and academia. The culmination of these efforts resulted in E&L recommendations to the USFDA. “Safety Thresholds and Best Practices for Extractable and Leachables in OINDP” was published in 2006 and since has been recognized by FDA and global regulatory authorities.

In 2008 the Parenteral and Ophthalmic Drug Product (PODP) L&E Working Group was formed to extrapolate the OINDP risk-based approach for evaluation and safety qualification of extractables and leachables in PODP. Specific factors associated with parenteral and ophthalmic drug products were considered that included patient population, dose, duration, and additional product-dependent characteristics. The PODP L&E Working Group conducted and evaluated the results of extraction studies on polymeric materials and evaluated a database of over 600 potential leachables using existing toxicological qualification approaches to justify thresholds for PODP. The proposed PODP identification and qualification thresholds were published in a 2013 manuscript followed by workshops. Subsequently, recommendations for “Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (PDP),” was thoroughly examined and consideration was given to factors related to new modalities. After rigorous review from industry and regulators a consensus was reached.

This document describes recommendations for E&L assessments of small volume, large volume parenterals and prefilled syringes with additional considerations for biological products. The field of biological products is rapidly advancing and with unique risks to product quality and patient safety. Study designs for E&L will consider intended use and regulatory jurisdiction and should be discussed early with the Regulatory Agency to understand proper application of the analytical evaluation threshold (AET), extraction concentrations, solvents, exposure conditions and analysis. There are unique considerations for ophthalmic drug products (ODP), and safety thresholds do not apply. Because of the unique considerations for ophthalmic drug products, extractables and leachables assessments are described in a separate manuscript entitled, “Principles for Management of Extractables and Leachables in Ophthalmic Drug Products.” PDA Journal of Pharmaceutical Science and Technology February 2022, pdajpst.2022.012744. DOI: <https://doi.org/10.5731/pdajpst.2022.012744>. Parenteral products administered by the intrathecal, intra-cerebroventricular, intra-articular, epidural, and perineural routes are out of scope. The PDP recommendations were the result of understanding a broad range of E&L applications over several years of building consensus with leaders in scientific and regulatory community. The views expressed in these documents are not necessarily those of individual companies or US Food and Drug Administration.

Contributions of individuals from the core team, extended teams, reviewers and advisors are sincerely appreciated. The members of the PODP L&E Working Group acknowledges the Product Quality Research Institute and its member organizations for providing this forum to make this collaboration possible. We also would like to recognize the dedicated scientists in volunteer laboratories that provided the essential data to make the recommendations possible.

The Working Group hopes that the recommendations contained in this document will serve to guide the pharmaceutical development process for PDP and facilitate the approval and manufacture of safe, effective, and quality medicines.

On behalf of the PQRI PODP L&E WG

Diane Paskiet, MS
Chair of PODP L&E Working Group
Chair of PQRI Steering Committee
Representing the Parenteral Drug Association

Douglas Kiehl, MS
Chair of Development Technical Committee
Representing the United States Pharmacopeia

Authors

Diane Paskiet, West Pharmaceutical Services Inc. Exton PA, USA
Douglas J. Ball, D&B ChemTox, LLC, Southbury, CT, USA
Dennis Jenke, Triad Scientific Solutions, LLC, Hawthorn Woods, IL, USA
Stephen A. Barat, HTG Molecular, Tucson, AZ, USA
Steve Beck, Xellia Ltd, Zagreb, Croatia
William P. Beierschmitt, D&B ChemTox, LLC, Southbury, CT, USA
James Castner, Pharma Interface Analysis, MA, USA
Thomas Egert, Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim/Rhein, Germany
Thomas Feinberg, FNA Pharma Consulting, LLC, Chapel Hill, NC, USA
Alan Hendricker, Becton Dickenson, Raleigh, NC, USA
Frank Holcombe, Jr., US Food and Drug Administration (USFDA), Silver Spring, MD, USA
Christopher Houston, Bausch & Lomb, Rochester, NY, USA
Desmond G. Hunt, United States Pharmacopeia, Rockville, MD, USA
Abigail Jacobs, US Food and Drug Administration (USFDA), Silver Spring, MD, USA
David Jones, Medicines and Healthcare products Regulatory Agency (MHRA), London, UK
Douglas Kiehl, Eli Lilly and Company, Indianapolis, IN, USA
Jacqueline A. Kunzler, Baxter Healthcare Corporation, Round Lake, IL, USA
Michael Lynch, Pfizer Groton, CT, USA
Ingrid Markovic, US Food and Drug Administration (USFDA), Silver Spring, MD, USA
Kumudini Nicholas, Health Canada, Ottawa, ON, Canada
Daniel Norwood, FNA Pharma Consulting, LLC, Chapel Hill, NC, USA
Mary Richardson, Iuvo BioScience, Rush, NY, USA
Timothy W. Robison, US Food and Drug Administration (USFDA), Silver Spring, MD, USA
Mike Ruberto, Materials Needs Consulting LLC, Montvale, NJ, USA
Edward Smith, Packaging Science Resources, Audubon, PA, USA
Cheryl LM Stults, C & M Technical Consulting, LLC, San Mateo, CA, USA
Alisa Vespa, Health Canada, Ottawa, ON, Canada

Observations made, opinions expressed and conclusions drawn in this publication reflect the views of the authors acting in their role as members of the PQRI Leachables and Extractables Working Group and should not be construed to represent the views or policies of their affiliated organizations.

Acknowledgments

Laboratory Services

Baxter Healthcare Corporation, Round

Lake, IL, USA

Roopang Shah

Marek Ciesla

Frank (Yousheng) Hua

Pfizer, Groton, CT, USA

Cindy Magee

Miguel Sandoval

Art Shaw

Becton Dickinson, Raleigh, NC, USA

Alan Hendricker

John Lennon

Bausch & Lomb, Rochester, NY, USA

Christopher Houston

John Rider

***Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, CT, USA & Ingelheim/Rhein, Germany***

Daniel L. Norwood

Scott Pennino

James O. Mullis

Thomas Egert

Jurgen Mattes

David Strassburger

Catalent Pharma Solutions, Morrisville, NC, USA

Paul Cvetich

Kimberly Davis

Michelle Cree

Tom Feinberg

Toxicology Services and Analysis

Pfizer Groton, CT, USA DEREK/Toxtree

Russell Naven

Patricia Ellis

TOX-RSA, LLC

Angela Howard

Brenda Seidman

ELSIE Consortium

Washington, D.C., USA

Intertox, Seattle, WA, USA

Rick Pleus

Gretchen Bruce

Nelson (Toxikon) Leuven, Belgium

Piet Christiaens

Christopher Brynczka

Biologics Subteam

Amgen, Thousand Oaks, CA, USA

Kim Li

Johnson & Johnson (Momenta Pharmaceuticals)

Cambridge, MA, USA

Jamie Tsung

Ophthalmics Subteam

IUVO BioScience, Rush, NY, USA

Mary Richardson

Bausch & Lomb, Rochester, NY, USA

Christopher Houston

AbbVie (Allergan), Irvine, CA, USA

Tao Wang

Brenda Birkestrand Smith

Andrea Desantis Rodrigues

Suppliers

Cameo Crafts Ltee-Ltd Saint-Laurent, Quebec, Canada

BASF Schweiz AG, Basle Switzerland (CIBA): Michael Ruberto

Schott Mainz, Germany: Horst Koller

Teknor Apex, RI, USA: Peter Gallard Pawtucket

West Pharmaceutical Services Inc. Exton PA, USA: Jeff Smythe

US Food and Drug Administration: Advisors/Reviewers

Xiaochun Chen, Division of Pharmacology-
Toxicology for Immunology &
Inflammation (DPT-II), CDER
Eleni Salicru, DPT-II, CDER
Luqi Pei, DPT-OII, CDER
Jackye Peretz, DPT-II, CDER
David Joseph, DPT-II, CDER

Taro Akiyama, DPT-CHEN, CDER
Rama Dwivedi, DPT-CHEN, CDER
Huiqing Hao, Division of Metabolic and
Endocrine Drug Products (DMEP), DPT-
CHEN,

Sree Rayavarapu, Division of
Pharmacology & Toxicology for
Cardiology, Hematology, Endocrinology
and Nephrology (DPT-CHEN), CDER
Marlene Kim, Office of the Commissioner
Naomi Kruhlak, Division of Applied
Regulatory Science (DARS), CDER
Curran Landry, DARS, CDER
Lidiya Stavitskaya, DARS, CDER

Dan Mellon, Division of Pharmacology-Toxicology
for Neurology (DPT-N), CDER

Carlic Huynh, DPT-N, CDER
Misol Ahn, DPT-N, CDER
Newton Woo, DPT-N, CDER
Irene Surh, DPT-N, CDER
Katie Sokolowski, DPT-N, CDER
Jaime D'Agostino, DPT-N, CDER
Jay Chang, DPT-N, CDER
Timothy McGovern, Office of New Drugs Immediate
Office (OND IO), CDER

Jane Sohn Office of Nonprescription Drug Products
(ONDP), CDER
Julia Pinto Office of Product Quality (OPQ), CDER

Valerie Amspacher, OPQ, CDER
Melanie Mueller, Office of Generic Drugs (OGD),
CDER
Narendranath Reddy Chintagari, OGD, CDER

PQRI Secretariat: Faegre Drinker Biddle & Reath LLP, Washington, D.C., USA

Lee Nagao
Jillian Brady
Mary Devlin Capizzi
Dede Godstre

Table of Contents

Part 1. Introduction and Summary of Recommendations	11
I. Introduction.....	11
II. Background and Scope	11
III. Recommendations	15
IV. References	16
Part 2. Justification of Thresholds for Leachables in PDP	18
I. Introduction.....	18
II. Parenteral Drug Products (PDP) Leachables Thresholds	20
A. QT Verification	23
B. SCT Verification	26
III. Conclusion	26
IV. References	30
Part 3. Best Practices for Extractables and Leachables Assessment in PDP	32
I. The Link between OINDP and PDP Best Practice Recommendations.....	32
II. Material/Component Characterization and Selection.....	34
III. Characterization Studies	36
IV. Leachables Assessment for Parenteral Drug Products	40
A. Parenteral Drug Product Dosage Forms	41
B. Migrants and Migration	48
C. Simulation Studies	49
D. Analytical Uncertainty	51
V. Conclusion	52
VI. References	52
Part 4. Special Topics: Considerations for Biological Products	54
I. Introduction.....	54
II. Context of Biological Products	55
III. Quality Considerations for Biological Products.....	56
IV. Manufacturing and Packaging Components in Contact with Biological Products ..	58
V. Suitability of Packaging and Delivery Systems	63
VI. Considerations for Qualification of CCS and Delivery System Components	63
VII. Lifecycle Management Example - Injectable Delivery Systems	65
VIII. Conclusion	66
IX. References	67
Part 5. Appendices	70
Appendix 1 List of Extractables and Leachables in the Database	70
Appendix 2: Method for Establishing the PDE	89
Appendix 3: Links to Publications by the PODP Working Group	92
Appendix 4: Glossary of Acronyms and Abbreviations.....	93

List of Tables

Table 3-1	Types of Controlled Extraction Studies	35
Table 3-2	Example of Estimated Leachable AET Values for SVPs and LVPs as a Function of Container	43
Table 3-3	Example of Estimated Leachable AET Values for SVPs and LVPs as a Function of Dose Volume	44
Table 3-4	Example Estimated Extractable AET Values for SVPs and LVPs as a Function of Component Mass	46
Table 4-1	Typical Applications for Manufacturing or Packaging Components and Risk Considerations	60
Table 4-2	Examples of Component Suitability Factors	63
Table 4-3	Examples of Common Formulation Excipients and Impact to Biological Products.....	64
Table 5-1	Values Used in the Calculations in this Document (from the ICH Q3D Guidance)	90

List of Figures

Figure 2-1	Process Flow for Qualification of Leachables in PDP	29
Figure 3-1	Example extractables profiles, in the form of Gas Chromatography/Mass Spectrometry Total Ion Chromatograms, from a typical PDP elastomer. [3] Top: 50:50 isopropanol:water; Middle: pH 9.5 aqueous; Bottom: pH 2.5 aqueous. Note that numbered extractables were identified, and ISTD refers to added internal standards. This type of extraction would represent that done for a multi-use component.	39
Figure 3-2	Consideration of the Analytical Challenge Associated with the Daily Dose Volume. The value of the AET is inversely proportional to the daily dose volume. Thus, drug products with a high daily dose volume will have low AETs.	50
Figure 4-1	Schematic of CCS Integration Over Biological Product Lifecycle.....	58